Skip to main content

How is SGD Pharma ready to meet this challenge?

Submitted by AdmNC on Mon, 05/10/2021 - 00:00

To help prepare this vaccine for worldwide distribution, SGD Pharma is offering access to our entire manufacturing output from our state-of-the-art ISO 15378 certified plant in Normandy, France, where our daily capacity stands at 400 to 500Ku of internationally recognized Type I neutral molded glass vials, available in many sizes including 10ml, 20ml, 30ml and 50ml.

What features of Type I molded glass make it suitable for the vaccine?

Submitted by AdmNC on Mon, 05/10/2021 - 00:00

Our Type I molded glass vials are resistant and chemically inert (thanks to their high hydrolytic resistance), making them a relevant solution to complete the Type I tubular glass vials offering and respond to this unprecedented surge in demand. They are ideal both to store and transport vaccines globally.

How has COVID-19 impacted the business?

Submitted by AdmNC on Mon, 05/10/2021 - 00:00

During 2020, SGD Pharma continued its daily operations and even improved performance in all plants, strengthened clients’ trust and gained market shares, accelerated R&D capabilities, and recruited and improved training efforts. Our plants in Asia and Europe are all subject to the highest level of safety measures to ensure the health and safety of employees while continuing manufacturing operations.

What are the specialisms of each of your factories?

Submitted by AdmNC on Mon, 05/10/2021 - 00:00

Two plants are best-in-class facilities dedicated to Type I glass (Saint-Quentin-Lamotte (SQLM) in Northern France and Vemula in India). SQLM is a Center of Excellence for Type I molded glass. Type II glass for anesthetics is produced in Sucy-en-Brie, France and Kipfenberg, Germany. Type III amber glass for analgesics is produced in Sucy-en-Brie. All manufacturing facilities are ISO 15378 certified. Vemula, India is also ISO 14001 and 18001 accredited.

Subscribe to